{"preliminary_commentary":{"by_channel":{"x_thread":19,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04787341\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"PARERE","nct_id":"NCT04787341","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=parere-nct04787341. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"PARERE","arms":[{"description":null,"label":"Panitumumab followed by Regorafenib","type":"ACTIVE_COMPARATOR"},{"description":null,"label":"Regorafenib followed by Panitumumab","type":"EXPERIMENTAL"}],"collaborators":["Bayer","Amgen"],"completion_date":{"date":"2026-05-28","type":"ACTUAL"},"conditions":["Colorectal Cancer"],"enrollment":{"count":213,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Regorafenib","otherNames":["panitumumab"],"type":"DRUG"},{"name":"Panitumumab","otherNames":["regorafenib"],"type":"DRUG"}],"last_update":"2026-08-28","lead_sponsor":"Gruppo Oncologico del Nord-Ovest","official_title":"Randomized Phase II Study of Panitumumab Rechallenge Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-type Chemorefractory Mestastatic Colorectal Cancer Patients","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2025-08-07","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall survival","timeFrame":"30 months"}],"references":[{"citation":"Ciraci P, Germani MM, Pietrantonio F, Manca P, Lonardi S, Busico A, Bergamo F, Burgio V, Mannavola F, Di Donato S, Fenocchio E, Palermo F, Capone I, De Grandis MC, Pella N, Scartozzi M, Antonuzzo L, Passardi A, Claravezza M, Salvatore L, Tamberi S, Randon G, Conca E, Conca V, Antoniotti C, Moretto R, Masi G, Boni L, Rossini D, Cremolini C; GONO Foundation Investigators. Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO. Ann Oncol. 2026 Jan;37(1):79-91. doi: 10.1016/j.annonc.2025.10.002. Epub 2025 Oct 18.","pmid":"41115464","type":"DERIVED"}],"start_date":{"date":"2020-12-15","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence","url":"https://clinicaltrials.gov/study/NCT04787341"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/parere-nct04787341"}